Relevant bibliographies by topics / Advanced or Metastatic Urothelial Carcinoma

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Advanced or Metastatic Urothelial Carcinoma'

Author: Grafiati
Published: 4 June 2025
Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Advanced or Metastatic Urothelial Carcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Vias, Poorva, Ashish Saklani, Suman Singh, Anantika Thakur, and Era Sankhyan. "Perinephric and Ovarian Metastasis from Advanced Urothelial Carcinoma Bladder: Case Report of a Rare Dismal Disease." Asian Pacific Journal of Cancer Care 9, no. 1 (2024): 207–10. http://dx.doi.org/10.31557/apjcc.2024.9.1.207-210.

Full text
Abstract:
Background: Metastatic urothelial carcinoma bladder at the time of diagnosis is a rare entity with lymph nodes, bones, lung and liver as common metastatic sites. Sometimes metastasis can be seen in various atypical sites.Case Presentation: Unusual location of metastasis can be seen in perinephric region, renal fascia and ovaries as seen in the described case. Primary urothelial carcinoma of ovary needs to be differentiated from the metastasis. There are no standard lines of management and the treatment needs to be individualised. Prognosis of metastatic urothelial carcinoma remains fatal with
APA, Harvard, Vancouver, ISO, and other styles
2

Wahyuni, Siska Dwiyantie, Sri Suryanti, Hasrayati Agustina, and Bethy Suryawathy Hernowo. "The Association of Clinicopathological Features with Metastatic Status in Infiltrative Urothelial Carcinoma of Bladder." Journal of Drug Delivery and Therapeutics 10, no. 6-s (2020): 99–102. http://dx.doi.org/10.22270/jddt.v10i6-s.4647.

Full text
Abstract:
Background: Infiltrative urothelial carcinoma of bladder is an aggressive variant of bladder carcinoma. Most of the patients in their first encounter with doctors are diagnosed with advanced stages and many has metastasized. Metastasis is a process of malignant tumor cells migrating from its primary tumor location to other organs or sites inside the body via blood circulation or lymphatic system. Metastasis process is responsible for 90% cancer deaths compared to the primary tumor itself, infiltrative urothelial carcinoma of bladder. To reduce mortality, knowledge of the clinicopathological ch
APA, Harvard, Vancouver, ISO, and other styles
3

Rizzo, Alessandro, Veronica Mollica, Matteo Santoni, et al. "Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis." Future Oncology 18, no. 6 (2022): 739–48. http://dx.doi.org/10.2217/fon-2021-0841.

Full text
Abstract:
Aims: Immune checkpoint inhibitors (ICIs) have recently revolutionized the treatment landscape of metastatic urothelial carcinoma. The authors performed a meta-analysis aiming to evaluate the predictive value of Eastern Cooperative Oncology Group performance status, age, sex, liver metastasis and histology in trials comparing first-line ICI-based combinations with chemotherapy in metastatic urothelial carcinoma patients. Methods: Hazard ratios were analyzed. Results: ICI-based combinations significantly decreased the risk of death in several clinicopathological subgroups, including patients wi
APA, Harvard, Vancouver, ISO, and other styles
4

Apolo, Andrea Borghese, Howard L. Parnes, Ravi Amrit Madan, et al. "A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma." Journal of Clinical Oncology 31, no. 15_suppl (2013): TPS4589. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4589.

Full text
Abstract:
TPS4589 Background: Accumulating evidence supports MET as a therapeutic target in urothelial carcinoma. Activated MET can promote angiogenesis and tumor growth by upregulating VEGF and may play a role in urothelial carcinoma pathogenesis. Cabozantinib inhibits primarily VEGFR2 and MET pathways. Cabozantinib has been approved by the FDA for the treatment of progressive metastatic medullary thyroid cancer, is in Phase 3 trials for metastatic castration-resistant prostate cancer and has demonstrated clinical activity in multiple solid tumors. We previously reported that shed MET levels in serum a
APA, Harvard, Vancouver, ISO, and other styles
5

Ullén, Anders, Firas Aljabery, Pär Dahlman, et al. "Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease." Scandinavian Journal of Urology 60 (March 25, 2025): 76–82. https://doi.org/10.2340/sju.v60.43236.

Full text
Abstract:
Objective: To overview and summarise the Swedish National Guidelines on Urothelial Carcinoma 2024. Methods: A narrative review of the updated guidelines was performed, highlighting new treatment recommendations for advanced and metastasized disease. Results: Compared to the previous guideline version, the current update includes recommendations for standardised radiological reporting when urothelial carcinomas are detected at CT-urography (CTU), to early identify locally advanced patients and accelerate the care pathway for these patients. The Swedish guidelines apply a more structured and lib
APA, Harvard, Vancouver, ISO, and other styles
6

Katims, Andrew B., Peter A. Reisz, Lucas Nogueira, et al. "Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma." Cancers 14, no. 21 (2022): 5431. http://dx.doi.org/10.3390/cancers14215431.

Full text
Abstract:
This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is still <1 year and there is an urgent need for alternative therapies. The advent of next-generation sequencing has allowed widespread comprehensive molecular characterization of urothelial tumors and, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis su
APA, Harvard, Vancouver, ISO, and other styles
7

Powels, Thomas, Park Se Hoon, Eric Voog, et al. "Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma." New Eng J Med 383, no. 13 (2020): 1218–30. https://doi.org/10.1056/NEJMoa2002788.

Full text
Abstract:
BACKGROUND. Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS. In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assess
APA, Harvard, Vancouver, ISO, and other styles
8

Rao, Arpit, and Manish R. Patel. "A review of avelumab in locally advanced and metastatic bladder cancer." Therapeutic Advances in Urology 11 (January 2019): 175628721882348. http://dx.doi.org/10.1177/1756287218823485.

Full text
Abstract:
Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failur
APA, Harvard, Vancouver, ISO, and other styles
9

Mainwaring, A. M., H. Wells, T. Banks, T. Ellul, and P. Bose. "Skeletal Muscle Metastasis to Vastus Lateralis from a Urothelial Carcinoma: A Case Report and Review of Its Diagnosis and Management." Case Reports in Urology 2019 (December 3, 2019): 1–4. http://dx.doi.org/10.1155/2019/8923780.

Full text
Abstract:
Bladder cancer is a common genitourinary tract malignancy. Urothelial carcinoma is the most frequent type of bladder cancer and it commonly metastasises to lymph nodes, bone, lung and liver by a haematogenous route. Skeletal metastases are very rare and are usually present in patients with advanced metastatic disease. We present an unusual case of a 71-year-old male with a urothelial carcinoma metastasis to the vastus lateralis muscle 3 months following a cystoprostatectomy for muscle invasive bladder cancer.
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, Chih-Chin, Po-Jung Su, and Yao-Chou Tsai. "Improved overall survival with immune checkpoint inhibitors in the treatment of metastatic urothelial carcinoma: A national retrospective comparative study." Journal of Clinical Oncology 42, no. 16_suppl (2024): e16550-e16550. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e16550.

Full text
Abstract:
e16550 Background: Numerous randomized trials have illustrated the survival advantages of immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma. However, the application of ICI varies in different trials, encompassing first-line, second-line, monotherapy, combination with chemotherapy, or maintenance therapy. Real-world clinical practices often diverge from trial criteria. This study aims to evaluate the effectiveness of any ICI regimen in treating metastatic urothelial carcinoma using real-world data. Methods: This retrospective comparative study included patients diagnosed wi
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Miller, Kurt, Rudolf Morant, Arnulf Stenzl, Manfred P. Wirth, and Ivan Zuna. "A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium." Karger, 2016. https://tud.qucosa.de/id/qucosa%3A70589.

Full text
Abstract:
Introduction: This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer. Methods: Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m 2 on days 1 and 8, and cisplatin 70 mg/m 2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential gefitinib (arm B); or alone (arm C). The primary endpoint was the
APA, Harvard, Vancouver, ISO, and other styles
2

Gagno, Sara. "Innovative strategies for tailoring therapy in cancer patient: pharmacogenetics and hormone therapy personalization in metastatic or locally advanced breast cancer patients treated with Exemestane." Doctoral thesis, Università degli studi di Padova, 2015. http://hdl.handle.net/11577/3423964.

Full text
Abstract:
Background: Response to chemotherapeutic agents is highly variable among patients both in terms of efficacy and tolerability; consequently personalization of drug therapy is one of the main objective in cancer treatment in order to reduce adverse drug reactions (ADRs), improve efficacy while decreasing the costs of treatments. Many factors account for inter-individual differences. Among them, patient’s genetic background has attracted interest for personalization of drug therapy (Pharmacogenetics). Breast cancer (BC) is the female most frequently diagnosed malignancy and the primary cause of
APA, Harvard, Vancouver, ISO, and other styles
3

Seisen, Thomas. "Caractérisation de l’évolution des tumeurs urothéliales de la voie excrétrice urinaire supérieure après néphrourétérectomie totale A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma." Thesis, Sorbonne université, 2018. http://www.theses.fr/2018SORUS486.

Full text
Abstract:
Même si la néphrourétérectomie totale représente le traitement de référence des tumeurs de la voie excrétrice urinaire supérieure (TVEUS), il existe un risque élevé de récidive post-opératoire qui peut survenir soit au niveau de la vessie soit dans la loge de résection et/ou sur le plan systémique. L’objectif de ce travail était de caractériser ces différents modes évolutifs. En ce qui concerne la récidive intra-vésicale, une revue systématique de la littérature avec méta-analyse a permis d’identifier les principaux facteurs de risque à la fois cliniques et anatomopathologiques. Par ailleurs,
APA, Harvard, Vancouver, ISO, and other styles
4

Ostheimer, Christian Emil Arthur Verfasser], Dirk [Akademischer Betreuer] Vordermark, Bernd [Akademischer Betreuer] Schmidt, and Daniel [Akademischer Betreuer] [Zips. "Prognostic and predictive significance of osteopontin and other hypoxia-related plasma proteins in the radiotherapy of locally advanced and metastatic bronchial carcinoma / Christian Emil Arthur Ostheimer. Betreuer: Dirk Vordermark ; Bernd Schmidt ; Daniel Zips." Halle, Saale : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2015. http://d-nb.info/1089085419/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tsai, Chia-Chun, and 蔡嘉駿. "Neoadjuvant chemotherapy improved survival rate in advanced urothelial carcinoma." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/71177945515676289830.

Full text
Abstract:
碩士<br>高雄醫學大學<br>醫學研究所<br>99<br>Objectives: Traditionally, radical surgery (RS) with adjuvant chemotherapy (AC) or radiotherapy is suggested for patients with advanced urothelial carcinoma (AUC). At present, some contemporary analyses indicate that systemic neoadjuvant chemotherapy (NC) has significant improvement in survival rate of patients with locally advanced bladder cancer. However, there are no well established criteria that would help to determine which treatment – NC or AC – should be administered to patients with AUC. Furthermore, few studies about the impact of NC on AUC in upper ur
APA, Harvard, Vancouver, ISO, and other styles
6

Laert, José Artur Veiga. "Revisão sistemática: tratamento do carcinoma espinocelular cutâneo avançado." Master's thesis, 2019. http://hdl.handle.net/10316/89850.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>INTRODUÇÃO: O carcinoma espinocelular cutâneo (CECc) é o segundo tipo mais comum de neoplasia da pele e a sua incidência tem vindo a aumentar ao longo das últimas décadas. A maioria dos CECc pode ser tratada com procedimentos simples, no entanto o tratamento da doença avançada está mal definido e, pela sua raridade, existem poucos ensaios clínicos disponíveis. Esta revisão sistemática tem como objetivo sumarizar as opções de tratamento disponíveis, focando nos avanços mais recentes. MÉTODOS: Foram realizada
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Mano, Roy, and Ofer Yossepowitch. Adenocarcinoma of the bladder. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0081.

Full text
Abstract:
Adenocarcinoma of the bladder accounts for 0.5–2 of bladder tumours. Risk factors include bladder exstrophy, bladder augmentation, schistosomiasis, and endometriosis. Bladder adenocarcinoma is classified as primary, arising from the bladder or urachal remnant, and secondary (metastatic). Most patients present with haematuria and irritative voiding symptoms. On imaging, a typical lesion is commonly located at the bladder dome. Compared to urothelial carcinoma (UC), most adenocarcinomas are diagnosed at high grade and advanced stage. Surgical treatment of localized disease entails partial cystec
APA, Harvard, Vancouver, ISO, and other styles
2

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text
Abstract:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led
APA, Harvard, Vancouver, ISO, and other styles
3

Huang, William C., and Ezequiel Becher. Advanced and Metastatic Renal Cell Carcinoma an Issue of Urologic Clinics. Elsevier, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Full text
Abstract:
Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading &gt;7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed
APA, Harvard, Vancouver, ISO, and other styles
5

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text
Abstract:
Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Song, Won Hoon, and Hyeong Dong Yuk. "Treatment of Metastatic Bladder Cancer." In Management of Urothelial Carcinoma. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-10-5502-7_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adorno Febles, Victor R., and Arjun V. Balar. "Immunotherapy for Metastatic Urothelial Carcinoma." In Bladder Cancer. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70646-3_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hung, Chao-Ming, Ching-Yu Huang, I.-Chang Lin, Shyh-An Yeh, Kai-Jen Lin, and Chao-Tien Hsu. "Urothelial Carcinoma (Metastatic) in Liver." In Surgical Pathology. Springer Nature Singapore, 2025. https://doi.org/10.1007/978-981-97-8995-5_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lerma, L. Angelica, Christopher M. Chandler, and Haodong Xu. "Metastatic Urothelial Carcinoma Versus Squamous Cell Carcinoma." In Practical Lung Pathology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-14402-8_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rudnik, Benjamin H., Scott G. Hubosky, Kim HooKim, et al. "Upper Tract Urothelial Carcinoma." In Advanced Ureteroscopy. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-82351-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Koshkin, Vadim S., and Petros Grivas. "Clinical Trials in Metastatic Urothelial Carcinoma." In Bladder Cancer. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-70646-3_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cosso, Federica, Martina Catalano, Giandomenico Roviello, and Gabriella Nesi. "Tumor Microenvironment in Urothelial Carcinoma: Focus on Metastatic Disease." In Handbook of Cancer and Immunology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-030-80962-1_79-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wong, Ching Yee Oliver, and Dafang Wu. "Case 83: Advanced/Metastatic Ovarian Carcinoma." In Phenotypic Oncology PET. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-09737-9_83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alhalabi, Omar, and Jianjun Gao. "Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma." In Urinary Bladder Pathology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71509-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Krabbe, Laura-Maria, Solomon L. Woldu, Oner Sanli, and Vitaly Margulis. "Metastatic Surgery in Advanced Renal Cell Carcinoma." In Urologic Oncology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-42603-7_65-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Watabe, Himemi, Yu Shimojo, Asako Shingu, et al. "Computational evaluation of the effect of tissue characteristics on photodynamic therapy of upper tract urothelial carcinoma using Monte Carlo-based light propagation simulation." In Advanced Photonics in Urology 2025, edited by Hyun Wook Kang, Ronald Sroka, and Jian J. Zhang. SPIE, 2025. https://doi.org/10.1117/12.3042826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Peña Hernández, J., A. Magdalena Pérez, J. Esquivel Negrín, et al. "4CPS-007 Efficacy and safety of avelumab in patients with locally advanced or metastatic urothelial carcinoma." In 29th EAHP Congress, Copenhagen, Denmark, 12-13-14 March 2025, Person centred pharmacy — Navigating digital health. British Medical Journal Publishing Group, 2025. https://doi.org/10.1136/ejhpharm-2025-eahp.82.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Jerry, Carlo Bello, Akash Khandelwal, Yulia Vugmeyster, Dana Nickens, and Swan Lin. "Abstract 1360: Exposure-response safety analysis of avelumab in patients with locally advanced or metastatic urothelial carcinoma." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skolnik, Jeffrey, Noah Hahn, Joaquim Bellmunt, et al. "Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Grivas, Petros, Alicia K. Morgans, Yair Lotan, et al. "Abstract CT178: Prevalence of PD-L1 expression in 1st-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zajac, M., A. M. Boothman, Y. Ben, et al. "Abstract 656: PD-L1 expression in primary lesions vs metastatic sites and by demographics in advanced urothelial carcinoma samples." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-656.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Skolnik, Jeffrey, Noah Hahn, Joaquim Bellmunt, et al. "Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-ct177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grivas, Petros, Alicia K. Morgans, Yair Lotan, et al. "Abstract CT178: Prevalence of PD-L1 expression in 1st-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-ct178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grivas, Petros, Min Yuen Teo, Nicholas Vogelzang, et al. "Abstract CT179: ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct179.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Jerry, Carlo Bello, Akash Khandelwal, et al. "Abstract 1361: Population pharmacokinetic modeling of avelumab to support flat dosing in patients with locally advanced or metastatic urothelial carcinoma." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1361.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Advanced or Metastatic Urothelial Carcinoma"

1

Qian, Jiekun, Zhangwei Tong, Yannan Zhang, and Chun Chen. Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.11.0060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jin, Hongyu, and Man Zhang. Adjuvant targeted therapy combined with surgery for advanced and metastatic renal cell carcinoma: Protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.11.0093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Cheng-Che, and Hao-En Lin. Survival Benefits and Bleeding Risk of Anti-VEGF Agents for Renal Cell Carcinoma (RCC): A Updated Systematic Review and Meta-Analysis of Phase 2 and 3 Randomized Clinical Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.3.0007.

Full text
Abstract:
Review question / Objective: To investigate the survival benefits (PFS, DFS, OS) and bleeding risk of the anti-VEGF agents compared with placebo or interferon alpha (IFNa) in patients with RCC. Condition being studied: Part 1. The hazard ratio (HR) of the progression-free survival (PFS) and overall survival (OS) of anti-VEGF agents vs. non/placebo for patients with unresectable, advanced, metastatic, renal cell carcinoma (RCC). Part 2. The HR of the disease-free survival (PFS) and OS of anti-VEGF agents vs. non/placebo for patients with post-nephrectomy RCC (adjuvant use). Part 3. The HR of th
APA, Harvard, Vancouver, ISO, and other styles
4

Chanvorachote, Pithi. Roles of nitric oxide, reactive oxygen species, and their derivatives in regulation of lung cancer cell metastasis. Chulalongkorn University, 2013. https://doi.org/10.58837/chula.res.2013.28.

Full text
Abstract:
The capability of cancer cells to resist to anoikis, migrate and invade surrounding tissues is associated with high metastatic potential and advanced stage of cancers. Recently, caveolin-1 (Cav-1) protein has garnered increased attention in implicating the aggressive behavior of cancer cells. We demonstrate herein that nitric oxide and hydrogen peroxide play a role in inhibiting anoikis process of lung cancer cells via caveolin-1 dependent mechanism. The Cav-1 function in inhibition of anoikis was demonstrated to be cause through Mcl-1 dependent mechanism. The present study demonstrated that C
APA, Harvard, Vancouver, ISO, and other styles
5

Contemporary systemic therapy for advanced urothelial carcinoma. BJUI Knowledge, 2018. http://dx.doi.org/10.18591/bjuik.0141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Advanced or Metastatic Urothelial Carcinoma' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography